AYUSH Regulatory Institutions ↔ Modern Pharmaceutical Regulatory Bodies

The Ministry of AYUSH, NCISM, CCRAS, NMPB, and the Drugs and Cosmetics Act's Chapter IVA compared against modern regulators like CDSCO and FDA; the API/AFI pharmacopoeial system corresponds closely to modern standards, but classical formulations are licensed on textual authority rather than trial evidence.

IN PLAIN LANGUAGE

This topic covers who regulates Ayurvedic medicines in India, how they are officially standardised, and how safety problems are supposed to be reported.

The Ayurvedic system has strong tools for verifying a drug's identity and purity and for defending traditional knowledge from patenting, but a classical formulation can be licensed simply for appearing in an old text — unlike a modern drug, which must show trial evidence of working before approval.

WHEN TO SEEK CARE

Not a clinical presentation; relevant to how a patient's herbal product came to be licensed and monitored.

🔴 REFER IMMEDIATELY

Never do this

Do not present an official pharmacopoeial monograph's therapeutic-uses listing as evidence that a drug has been shown to work.

🟢 SUITABLE FOR ROUTINE / COLLABORATIVE CARE

AYURVEDA SCOPE

Not a clinical topic; concerns regulatory structure, standards, and pharmacovigilance reporting for ASU drugs.

MODERN MEDICINE SCOPE

Not a clinical topic; the modern-side content is pharmaceutical regulatory and adverse-event reporting structure.

COLLABORATIVE SCOPE

Any practitioner encountering an unexpected reaction to an Ayurvedic medicine should report it to the national ASU pharmacovigilance programme regardless of their own system of training.

Sign in to read the full comparison

The plain-language summary and safety guidance above are free for everyone. The 10-dimension scholarly comparison needs an account.